
Metagenomic NGS for Pathogen Detection: Quality Control Issues and Strategies

Steve Miller MD PhD Department of Laboratory Medicine University of California San Francisco


Disclosures

- Major funding provided by:
 - CA Initiative to Advance Precision Medicine
 - Sandler and Bowes Foundations
 - Schwab Foundation
 - Marcus Foundation

mNGS Pathogen Detection



mNGS Assay Workflow



CLIA Implementation of mNGS

- Required for patient testing

 Laboratory Developed Test (LDT)
- Protocol Development
- Assay Validation
- Quality Control / Quality Assurance
 - Staff Training / Competency
 - Proficiency Testing

Quality Control Approach

- Adapted from CLIA Regulations
 QA/QC monitoring
- Failure Mode Analysis
 - Likely points of assay failure
 - Develop method to detect failure
- Assay Monitoring
 - Define expected performance
 - Monitor changes over time

Quality Control Methods

- Reagent Quality Control
- External Controls
- Internal Controls
- Process Controls / Checkpoints
- Contamination Control

Reagent Quality Control

- What reagents need QC?
- How to perform?
- What are acceptible criteria?

Reagent QC

- Define "Critical" Reagents
 - Enzymes
 - Major assay steps
 - Confirm performance before putting into use
 - External control mNGS or surrogate assays acceptable
- Non-critical reagents
 - Manufacturer QC acceptable
 - Confirm acceptability using external control results

Critical Reagent Log

(Very partial list)

Baseline DNase	Epicentre - Illumina
C.neoformans	American Type Culture Collection
DNA Clean & Concentrator Kit -5 Capped Columns	Zymo Research
dNTPs	Thermo Fisher - Invitrogen
EZ1 Virus Mini Kit v.2.0	QIAGEN
HiSeq Rapid SR Cluster Kit v2 Flowcell	Illumina
HiSeq Rapid SR Cluster Kit v2 Rapid SR Cluster Kit	Illumina
HiSeq Rapid SR Cluster Kit v2 Flowcell	Illumina
K.pneumoniae	American Type Culture Collection
Linear acrylamide	Thermo Fisher - Life Technologies
Lysing Matrix B Tube (2mL)	MP Biomedicals
MS2 Phage	American Type Culture Collection
NEBNext Microbiome DNA Enrichment Kit	NEBNext (New England Biolabs)
Nextera Index Kit v2 Set A (96 indexes, 384 samples)	Illumina
Phusion High-Fidelity PCR Kit	Thermo Fisher - Life Technologies
SEQUENASE VERSION 2.0 DNA POLYMERASE - UNDILUTED	Affymetrix
Superscript III enzyme	Thermo Fisher - Invitrogen
Synthetic CSF Matrix 100 mL	Golden West Biologicals
T1 Phage	American Type Culture Collection
Turbo Dnase Kit	Thermo Fisher - Ambion
Water, (DNASE, RNASE free), Fisher BioReagents	Fisher Scientific
Buffer EB	Qiagen
Water, (DNASE, RNASE free), Fisher BioReagents	Fisher Scientific

Include: Enzyme kits Control organisms Sterile materials

QC metric: Prior to use Activity Contamination

External Controls

Positive Control

Representative Organism	Pathogen Category	Genus	Family	LoD	Units
CMV	DNA Virus	Lymphocryptovirus	Herpesviridae	9.41	copies/mL
HIV	RNA Virus	Lentivirus	Retroviridae	100.75	copies/mL
K.pneumoniae	Gram(-) Bacteria	Klebsiella	Enterobacteriaceae	8.71	CFU/mL
S.agalactiae	Gram(+) Bacteria	Streptococcus	Streptococcaceae	8.92	CFU/mL
A.niger	Mold	Aspergillus	Aspergillaceae	130.06	CFU/mL
C.neoformans	Yeast	Filobasidiella	Tremellaceae	0.01	CFU/mL
T.gondii	Parasite	Toxoplasma	Sarcocystidae	55.06	organisms/mL

Negative Control


- Elution buffer (negative extract)
- Also used as background normalizer


Internal Controls


Control	Concentration	Average % reads	CV % reads	Threshold number of reads
MS2 phage (RNA)	10 ³ cp/ml	0.011	49.5%	>= 100
T1 phage (DNA)	10 ⁵ cp/ml	0.022	29.8%	>= 100

Controls for entire test process

Low number of IC reads in high background samples (decreased sensitivity)









Process Controls

- Library Quality
 - Library Size
 - Library Concentration
- Sequencing Quality
 - Cluster Density
 - -Q score > 30





Analyzer Controls

- Concentration controls (Qubit)
 - Stock libraries
- Bioanalyzer controls
 - Stock libraries
- Develop metrics for QC of library analyzers
 - Concentration range
 - Size range

Periodic Monitoring

- Positive threshold verification
 - Verify detection at 1:10 dilution of positive control
- Software run log
 Document versions
- Instrument repair log
- Troubleshooting log

SOFTWARE VERSION INFORMATION

Contamination Control

- NGS assay extremely sensitive to contamination
 - Initial sample
 - Library preparation
 - Instrument carryover
- Double barcoded adaptors




- Need caution interpreting significance of a few sequence reads when high positive sample is on same or recent run
- Bacterial background reads complicate detection of low levels of bacteria in clinical samples
- Use ratio of bacteria, fungal and parasite reads to NTC
 - Threshold of 10x reads in sample compared to NTC

Contamination Control

- Swipe Tests
 - Background laboratory contamination
 - Amplicon
 - Organisms
- What is successful swipe test?
 - Assess flora
 - Unusual detections
 - Pathogenic organisms

Swipe Test Results



Environmental bacterial / fungal flora - acceptable Few reads to potentially pathogenic viruses – clean and repeat

Contaminant Database

- Track contamination over time
 - -NTC
 - -PC
 - Samples
 - Swipe tests


NTC Contaminants

Species	Genus	Family	tag	Reads	-	<141 bp fami	is pathogen
		Adenovirida			518		TRUE
Alphapapillo	Alphapapillo	Papillomavir	host-01 hu	m 15	472		FALSE
				0			FALSE
*	*	Papillomavir	host-01 hu	m 6			FALSE
Musca hytrov	Muscavirus	Hytrosavirida	host-07 inv	re 23	140		FALSE
Autographa d	Alphabaculo	Baculovirida	host-07 inv	'є 14	276		FALSE
Merkel cell p	Polyomaviru	Polyomavirio	host-01 hu	m 24	140		FALSE
Citrus endog	enous parare	Retroviridae	host-01 hu	m 101			FALSE
Murine leuke	Gammaretro	Retroviridae	host-02 ve	rt 14	256		FALSE
Human papil	lomavirus	Papillomavir	host-01 hu	m 14			FALSE
Autographa d	Alphabaculo	Baculovirida	host-07 inv	'e 1	272		FALSE
Alphapapillo	Alphapapillo	Papillomavir	host-01 hu	m 39	380		FALSE
*	*	Papillomavir	host-01 hu	m 1			FALSE
*	Alphabaculo	Baculovirida	host-07 inv	re 20			FALSE
Gammapapil	Gammapapil	Papillomavir	host-02 ve	rt 14	140		FALSE
Geobacillus	/irus E2			49			FALSE

Troubleshooting Example


- Failure to achieve sufficient reads per library
 - 5 million required for adequate analysis
 - Interpreted with comment that sensitivity may be decreased
- Why are some libraries not providing enough sequence?

Sequencing Instrument



Total number of reads per run fairly constant


Library Quantification



Low number of reads from libraries with lower final concentration Even after correcting for this in the pool

Low input libraries tend to have non-adaptor DNA present Alternative normalization strategies investigated Add more library to pool Quantify with kappa PCR or MiSeq run

Overview – mNGS QC



Summary – mNGS QA

- Incorporate standard QC and Risk-Based approaches
- Many QC criteria / checkpoints
 - External controls
 - Internal controls
- Process controls
 - Workflow
 - Contaminant databases
- Assay maintenance
 - Results correlation
 - Investigate usual results / QC trends

- Checkpoint Metrics
- Contamination Control
- Reagent QC
- Swipe Tests
- Proficiency Testing

Acknowledgements



UCSF Chiu Lab and VDDC Charles Chiu, MD/PhD Erik Samayoa, CLS Shaun Arevalo, CLS Becky Fung, CLS Hannah Sample, BS Samia Naccache, PhD Scot Federman, BS Doug Stryke, BS Joseph DeRisi, PhD Michael Wilson, MD Jeffrey Gelfand, MD Michael Geschwind, MD



Berkeley

UCLA



<u>UCLA</u> Jeffrey Klausner, MD/MPH Romney Humphries, PhD (ABMM)

<u>University of California,</u> <u>Berkeley</u> Brent Fulton, PhD/MBA <u>UCDavis</u> Chris Polage, MD Stuart Cohen, MD

<u>Children's Hospital Los Angeles</u> Jeffrey Bender, MD Jennifer Dien-Bard, MD <u>Children's National Medical Center</u> Brittany Goldberg, MD Joseph Campos, MD

<u>St. Jude's Medical Center</u> Randall Hayden, MD/PhD

Many Acute Infectious Diseases Remain Undiagnosed






Diarrheal Disease Up to 50% unknown cause Meningitis / Encephalitis 60-80% unknown cause

Pneumonia 15 – 25% unknown cause



Fever / Sepsis ~20% unknown cause


Nearly All Agents that Cause Infectious Diseases Contain Nucleic Acid (DNA/RNA)



Bacteria




Viruses



Fungi



Parasites




NGS Pathogen Detection Allows For

- Diagnosis
 - Treatment optimization
- Pathogen Discovery
- Public Health Investigation
 - Unknown outbreak


Bioinformatics Challenges







GenBank Size

Rate of DNA Sequencing





RAPSEARCH




Sequence Based Ultra-Rapid Pathogen Identification (SURPI)


Interpretative report




Coverage map



Taxonomic classification





SURPI visualization tool

SURPIviz Contact SURPI Runs -

Signed in as chiulab.shared@gmail.com Sign out


SURPIviz


The visual home of SURPI, a cloud-compatible bioinformatics pipeline for ultrarapid pathogen identification from next-generation sequencing of clinical samples.


Learn more »


View results from the SURPI runs below:


#	SURPI Run	Output files	Heat maps	Krona plots	Coverage maps
0	Demo Clinical	Output files	Heat maps	Krona plots	Coverage maps
1	Demo Spike-in	Output files	Heat maps	Krona plots	Coverage maps
2	1PilotBoardMeeting	Output files	Heat maps	Krona plots	Coverage maps
3	131025 JLG A1N2DNAseTest	Output files	Heat maps	Krona plots	Coverage maps















Validation of NGS

- Development of Controls
- Assay Performance Characteristics
- Contamination Control
- Clinical Study Precision Diagnosis of Acute Infectious Disease
 - Interesting Case Reports & Discussion

Assay Sensitivity



Spiked Viral Titer (copies/mL, log scale)




Results-based accuracy (after discrepancy testing)

		ClinMicro Reference Lab			
		Pos	Neg	Untested	Total
mNGS	Pos	68	7	22	97
	Neg	11	327		338
	Total	79	334	22	
Sensitivity TPR	TP/(TP+FN)	86.1			
Specificity TNR	TN/(TN+FP)	97.9			

Contamination Control


- NGS assay extremely sensitive to contamination
 - Initial sample
 - Library preparation
 - Instrument carryover





- Need caution interpreting significance of a few sequence reads when high positive sample is on same or recent run
- Bacterial background reads complicate detection of low levels of bacteria in clinical samples
- Use ratio of bacteria, fungal and parasite reads to NTC
 - Threshold of 10x reads in sample compared to NTC


Precision Diagnosis of Acute Infectious Disease



mNGS Clinical Cases

- From Mexico
- 1 month PTA, she was admitted to a local hospital in Mexico due to HA, nausea, abnormal jerking movements of fingers, hands, and legs.
- CSF showed 183 WBC (100% mono), glucose 25, protein 270
 EBV and HHV-7 detected in CSF
- She was treated with acyclovir, then ganciclovir.
- 2 weeks after discharge, she developed back pain and worsening HA.

- Repeat admission for worsening symptoms
- Brain MRI w/ + w/o contrast: normal
- CSF showed WBC 137 (L91%), glu 25, prot 200 Negative Gram-stain, bacterial culture Negative HSV PCR, EBV PCR, enterovirus PCR
- Multiple ID tests (blood and CSF) were sent
- INH, rifampin, PZA, ETB + pyridoxine initiated for empiric coverage of tuberculosis



- Clonazepam added for polyminimyoclonus
- Negative CSF *M. tb* PCR
- No improvement after 8 days of therapy repeat LP
- CSF (#2): WBC 176 (N53%, L38%, M9%), glucose 25, protein 131.

CSF#2 was positive for EBV PCR (Ct=36.44) and HHV-7 PCR

- EBV serology: c/w remote infection
- Blood for EBV PCR was not detected
- Concern for drug-resistant TB:
 - ETB was changed to ethionamide
 - Levofloxacin added to RIPE

- TB PCR CSF #2 negative
- she improved substantially and was discharged home with <u>5 anti-TB medications</u>
- At 1 week and 1 month follow-up after discharge, she had near resolution of symptoms, but still reported several episodes of shaking of her extremities
- Because of clinical improvement, she returned to Mexico and continued her anti-TB therapy.
- CSF #2 submitted for mNGS analysis

Reads per Million Normalized to NTC

- Accession: All Prep: DNA RNA Batch: A160129
- Brucellaceae Brucellaceae Lachnospiraceae Enterobacteriaceae Corynebacteriaceae Burkholderiaceae Pseudomonadaceae Brucellaceae Lactobacillaceae


Lactobacillaceae Nostocaceae Sphingobacteriaceae Geodermatophilaceae Micrococcaceae Lactobacillaceae Brucella Brucella Blautia Pantoea Corynebacterium Burkholderia Pseudomonas declassified Lactobacillus


Ŧ.

Lactobacillus Anabaena Sphingobacterium declassified Arthrobacter Lactobacillus

RPM ratio = 15.7

Brucella melitensis [Ruminococcus] torques Pantoea rwandensis Corynebacterium vitaeruminis Burkholderia contaminans Pseudomonas poae declassified Lactobacillus sakei sugarcane isolate 74-1 Lactobacillus fermentum Anabaena variabilis Sphingobacterium sp. ML3W declassified Arthrobacter arilaitensis Lactobacillus johnsonii MA_123_133 MA_125_135 MA_125_135 MA_126_136 MA_127_137 MA_129_139 MA_129_139 MA_131_141 MA_131_141 MA_132_142





https://surpiviz.ucsf.edu/heatmap/surpi_clin_HVald004_EP_ES_160201/

Followup

- Patient started on targeted Brucella therapy
 - Doxycycline + Rifampin
- Symptoms fully resolved in 2 weeks
- Serum antibody agglutination positive 1:80 titer
- PCR performed confirming mNGS findings of Brucella DNA

- History of idiopathic pulmonary fibrosis s/p bilateral lung transplant, migraines, hypercoagulability with DVT, and multiple sclerosis (MS) on chronic immunosuppression
- Admitted 8 days of fever, headache, refractory nausea/vomiting, neck stiffness, and photophobia
- Had been hospitalized prior complaining of "worst headache of her life" – treated with abortive migraine medications with only partial relief


- Resident of southern California
- Denied sick contacts, pets, insect bites, or eating shellfish or game meats
- Reported travel to mountains in Utah in Aug 2016, the Caribbean in 2010, and throughout Europe decades prior to admission
- Outpatient medications notable for immunosuppressive agents (tacrolimus, mycophenolate mofetil, prednisone, teriflunomide) and antimicrobial prophylaxis with trimethoprim/sulfamethoxazole and acyclovir; also on an intrathecal morphine pump

- On admission
 - Fever to 38.3° C, otherwise vital signs normal
 - Physical exam remarkable only for R leg tenderness attributed to known DVT
 - Initial laboratories remarkable for stable pancytopenia (WBC 9, HgB 10.9, platelets 124,000), mildly elevated LFTs (AST 130 U/L, ALT 83 U/L, total bili 1.1 mg/dL, alkaline phosphatase 144 U/L) and borderline elevated prothrombin time of 14.3 (11-14 seconds)
 - MRI baseline periventricular and subcortical T2/FLAIR white matter intensities associated with her MS, no acute changes
 - Started on empiric vancomycin, ceftazidime, acyclovir, voriconazole
- <u>Lumbar puncture performed on day 3</u>
 - CSF pleocytosis (10 WBC/mm63; 88% lymphocytes; 12% monocytes; protein 29; glucose 48)


Microbiological Studies Negative for Etiology

Hospitalization at UCLA (Oct 2016)	Hospitalization at UCLA (Nov 2016)
Blood CMV DNA quantitative PCR Cryptococcal Antigen EBV PCR detected <10 HSV-1 and 2 PCR Fungal Culture Bacterial Culture Toxoplasma gondii DNA PCR MTB-Quantiferon-Gold Adenovirus DNA PCR Parvovirus B19 DNA PCR West Nile IgG and IgM Rickettsia RMSF and typhus IgG and IgM Varicella zoster DNA PCR Coccidioides IgG and IgM EIA Hepatitis A Ab total Hepatitis A Ab IgM	Blood Hepatitis A IgM Hepatitis B core IgM Hepatitis B surface antigen Hepatitis C Antibody HBV DNA PCR Cryptococcal antigen HIV 4 th generation Ag/Ab JCV Ab 2.31 (>0.40 positive) RPR Aspergillus antigen EIA Coccidioides IgG/IgM EIA Toxoplasma gondii DNA PCR Peritoneal fluid Bacterial gram stain and Culture
CSF Cryptococcal Antigen Enterovirus PCR Fungal Culture Bacterial gram stain and culture Varicella Zoster PCR HSV 1 and 2 PCR CMV DNA quantitative PCR	Nasal swab Respiratory Virus Panel PCR

- By day 6, patient clinically improved with resolution of all symptoms and fever, except for mild persistent headache
- Discharge diagnosis was meningoencephalitis due to viral infection or tacrolimus toxicity
- mNGS performed on CSF sample obtained on day 3



Distribution of 11 Blast Hits on the Query Sequence 😡



scriptions


Sequences producing significant alignments:


Select: All None Selected:0

Alignments 🗒 Download 🖂 GenBank Graphics Distance tree of results						
Description		Total score	Query cover	E value	Ident	Accession
Swine hepatitis E virus strain swSTHY12-VAS19/2003/CA, complete genome	193	193	97%	1e-45	92%	KJ507955.1
Hepatitis E virus isolate GISw, partial genome	187	187	97%	5e-44	91%	KF303502.3
Hepatitis E virus genes for nonstructural polyprotein, hypothetical protein, capsid protein, complete cds, isolate: JRC-HE3	187	187	97%	5e-44	91%	AB630971.
Hepatitis E virus strain HEV-US1 polyprotein (ORF1) gene, partial cds; and (ORF3) and capsid protein (ORF2) genes, complete cds	187	187	97%	5e-44	91%	AF060668.
Hepatitis E virus genomic RNA, complete genome, isolate: JKN-Sap	182	182	97%	2e-42	91%	AB074918
Hepatitis E virus genomic RNA, complete genome, clone: swMN06-A1288	176	176	97%	1e-40	90%	AB290312.
Hepatitis E virus isolate Sing-HEV01, complete genome	171	171	95%	5e-39	90%	KT447526.
Hepatitis E virus isolate Sing-HEV23, complete genome	165	165	95%	2e-37	89%	KT447528.
Hepatitis E virus genomic RNA, complete genome. isolate: wbJSG1	165	165	97%	2e-37	88%	AB222182
Swine hepatitis E virus genomic RNA, complete genome, isolate; swJB-M8	159	159	97%	1e-35	88%	AB481228
Swine hepatitis E virus genomic RNA, complete genome, isolate: swJR-P5	154	154	97%	5e-34	87%	AB481229




Hepatitis E virus genomic RNA, complete genome, isolate: HE-JA10





- Diagnosis of HEV-associated meningoencephalitis communicated to patient
- Retrospective review of EMR showed normal transaminase levels prior to lung transplantation, with persistent low-level transaminase elevations following transplantation in 2011
- Immediate follow up HEV testing showed serum IgM positivity, negative IgG, and plasma HEV viremia (5,960,000 IU/mL)
- Ribavirin monotherapy was started for this patient
- Case reported to United Network for Organ Sharing donor safety net
- HEV IgG/IgM donor serum was positive, but HEV RNA not detected
 - Potential donor-derived infection

Patient LFTs



Hepatitis E – Neurologic Manifestations

- Commonest cause of Acute hepatitis worldwide
- Neurological disorders associated with HEV
 - First case- 2000: GBS
 - 2011: 5.5% of well characterized patients with acute and chronic Hepatitis E cases from Europe
 - 100 cases reported to date

Box 1 Neurological manifestations of hepatitis E Conditions in which there is probably a causal relationship (n = cases reported)

- Guillain–Barré syndrome (n = 36)
- Brachial neuritis (n = 30)
- Meningoencephalitis (*n* = 12)

Conditions in which causality remains to be established (n = cases reported)

- Mononeuritis multiplex (n = -6)
- Bell's palsy (n = 3)
- Myositis (n = 2)
- Vestibular neuritis (n = 1)
- Peripheral neuropathy (*n* = 1)

Case Discussion

- First report of potential HEV transmission via lung transplantation
- Evidence in support: positive anti-HEV IgG/IgM testing of donor serum
- Persistent low-level transaminase elevations posttransplant
- Prior HEV donor transmission reports include liver transplant recipient and 2 renal transplant recipients (from same donor)
 - (Sclosser, et al., J hepatol 2012; Pourbaix, et al., Transplant Infect Dis 2016)

68 year old male with fever and AMS


- History of CAD, HTN, mantle cell lymphoma
- Developed fever, chills lethargy, fatigue, confusion
- Admitted and started on empirical vancomycin, meropenem and levofloxacin
- 3 days later became hypoxic with worsening AMS
 - LP showed 18 WBC (35% monocytes, 33% lymphocytes, 32% neutrophils), normal glucose and protein
- Added acylovir for viral meningitis


68 year old male with fever and AMS

- Patient was retired oil field worker living in Kern County, CA
- Dog owner
- Recent travel to mountains of Arizona

68 year old male with fever and AMS

- Patient continued to spike fevers
 - Antifungal therapy added
- Repeat LP showed persistent pleocytosis
 - Extensive infectious workup non-revealing
- CSF analyzed by mNGS






Descriptions

Sequences producing significant alignments: Select: All None Selected:0 Alignments Bownload - GenBank Graphics Distance tree of results Ø. Max Total Query E Description Ident Accession score score cover value St. Louis encephalitis virus isolate 39, complete genome 254 254 100% 5e-64 99% KX258462.1 St. Louis encephalitis virus isolate 2281, complete genome 254 254 100% 5e-64 99% KX258461.1 St. Louis encephalitis virus isolate 43, complete genome 254 254 100% 5e-64 99% KX258460.1 St. Louis encephalitis virus strain CbaAr-4005, complete genome 254 254 100% 5e-64 99% FJ753286.2 St. Louis encephalitis virus strain RT 121B polyprotein gene, complete cds. 250 250 100% 6e-63 99% KT823415.1

St. Louis encephalitis virus (gi|537790028|, 10936 bp)


St. Louis encephalitis virus strain CbaAr-4005, complete genome



St. Louis Encephalitis Virus

- Normally self-limiting
- Can be prolonged / severe in immunocompromised patient
- Patient continued to deteriorate with supportive care
 - Placed on comfort care and passed away
- Autopsy revealed mantle cell lymphoma and aspiration pneumonia

SLEV Reintroduced into North America from Argentina




Case Discussion

- SLEV re-introduced into Arizona in 2014 from Argentina
- Sequence analysis shows most similar to mosquito pool from Kern County, CA
 - Patient likely acquired locally rather than from trip to Arizona
- Patient immunocompromised due to underlying disease leading to fatal infection


55 y/o male with deafness and behavioral change

- 55 y/o male with bone marrow transplant for CLL. Prior immunosuppressive therapy. In mid-October, developed rapidly progressive hearing loss over 2-3 weeks.
- CSF unremarkable; MRI negative; PCR for HSV and enterovirus negative; treated empirically with high-dose valacyclovir, antibiotics, IVIg and steroids daily to no effect
- Over next few weeks, developed nausea, fatigue, ataxia, persistent hearing loss, then depressed, irritable mood (unusual for patient per his wife).
- Repeat MRI late December → abnormal signal in thalamus and midbrain bilaterally; frontal lobe biopsy performed (only accessible region)



Right frontal lobe

White matter



GFAP stain

Diffuse

reactive

gliosis

CD3 stain

T lymphocytes

CD8 stain

Micro


Microglial activation

CD8 stain


Microglial activation

CD8 stain


Microglial cell processes in proximity to neurons



Genome Assembly of a Novel Astrovirus




DNA *In situ* Hybridization of Brain Tissue For Astrovirus



Neuronal cytoplasmic staining


"Encephalitic" Astrovirus Clade in Humans



Volume 16, Number 6–June 2010 Research

Astrovirus Encephalitis in Boy with X-linked Agammaglobulinemia

Phenix-Lan Quan, Thor A. Wagner, Thomas Briese, Troy R. Torgerson, Mady Hornig, Alla Tashmukhamedova, Cadhla Firth, Gustavo Palacios, Ada Baisre-De-Leon, Christopher D. Paddock, Stephen K. Hutchison, Michael Egholm, Sherif R. Zaki, James E. Goldman, Hans D. Ochs, and W. Ian Lipkin 🖂



Case Discussion

• Patient started on ribavirin and IVIg

• Origin of virus unknown, but presumably communityacquired

 Despite treatment, he continued to deterioriate, and passed away

Summary

- NGS assay shows acceptable performance for clinical testing
 - Current study investigating utility of CSF testing
 - Evaluation of other sample types (plasma for sepsis, BAL for pneumonia)
- Allows for diagnosis of severe infections of unknown etiology after extensive conventional testing
 - Sensitive and specific but some limitations
 - Pathogen DNA may be transient / serology used for diagnosis
 - Contamination control important
- Pathogen detection can guide optimal therapy

Acknowledgements



UCSF Chiu Lab and VDDC Charles Chiu, MD/PhD Erik Samayoa, CLS Shaun Arevalo, CLS Becky Fung, CLS Hannah Sample, BS Samia Naccache, PhD Scot Federman, BS Doug Stryke, BS Joseph DeRisi, PhD Michael Wilson, MD Jeffrey Gelfand, MD Michael Geschwind, MD



Berkeley

UCLA



<u>UCLA</u> Jeffrey Klausner, MD/MPH Romney Humphries, PhD (ABMM)

<u>University of California,</u> <u>Berkeley</u> Brent Fulton, PhD/MBA <u>UCDavis</u> Chris Polage, MD Stuart Cohen, MD

<u>Children's Hospital Los Angeles</u> Jeffrey Bender, MD Jennifer Dien-Bard, MD <u>Children's National Medical Center</u> Brittany Goldberg, MD Joseph Campos, MD

<u>St. Jude's Medical Center</u> Randall Hayden, MD/PhD